Study Author Discusses 3-Year Data on Lebrikizumab

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
DermWire TV
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
DermWire TV Extra: SDPA President Amber Blair, PA-C, Previews Her New Column
DermWire TV Extra: SDPA President Amber Blair, PA-C, Previews Her New Column
DermWire TV
DermWire TV Extra: SDPA President Amber Blair, PA-C, Previews Her New Column
- Amber Blair, PA-C
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
DermWire TV
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
DermWire TV
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined

DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab